Reforms Subcommittee on National Security, 2.73. Mazzuchi, 261; e Atlas, 15767.74. Sidell, 441; e Raymond A. Zilinskas, Iraqs Biological Weapons: The Past as Future?Journal of the American Medical Association 278, no. 5 (August 1997): 41824.75. Office of Technology Assessment, US Congress, Proliferation of Weapons of Mass Destruction, Publication OTA-ISC-559 (Washington, D.C.: Government Printing Office, 1993), 5355; e Information about the Anthrax Vaccine, 3.76. Robert H. Kupperman e Darrell M. Trent, Terrorism: Threat, Reality, Response(Stanford, Calif.: Hoover Institution Press, 1979), 57; Information about the Anthrax Vaccine, 3; e Atlas, 15767.77. Carus, Biological Warfare Threats in Perspective, 14955.78. Atlas, 160.79. Pentagon Spokesmans Regular Briefing.80. Carus, Biological Warfare Threats in Perspective, 154.81. DoD Response to the Staff Report of the House Government Reforms Subcommittee on National Security, 1, 2; e Information about the Anthrax Vaccine, 2.82. Peter Grier, Up in the Air about Anthrax, Air Force Magazine 82, no. 10 (October 1999): 6871.83. Atlas, 160; e Raymond A. Zilinskas, Verifying Compliance to the Biological and Toxin Weapons Convention, Critical Issues in Microbiology 24, no. 3 (1998): 195218.84. Hoffman, A-17.85. Zilinskas, Verifying Compliance, 195218; e Remarks of Dr. Brad Roberts.86. Zilinskas, Verifying Compliance, 195218; e Rolf Ekeus, UN biological Inspections in Iraq, in The New Terror: Facing the Threat of Biological and Chemical Weapons,24647.87. Ekeus, 23754.88. Plague War: What Happened in South Africa?89. Ibid.90. Arthur M. Friedlander et al., Postexposure Prophylaxis against Experimental Inhalation Anthrax, Journal of Infectious Diseases 167 (May 1993): 123943.91. Philip S. Brachman et al., Field Evaluation of Human Anthrax Vaccine, American Journal of Public Health 52 (April 1962): 63245.92. P. Hambleton, J. A. Carmen, e J. Melling, Anthrax: The disease in relation to vaccines, Vaccine 2 (1984): 12532.93. B. E. Ivins et al., Efficacy of a standard human anthrax vaccine against Bacillus anthracis aerosol spore challenge in rhesus monkeys, Salisbury Medical Bulletin 87, supplement (1996): 12526.94. Arthur M. Friedlander, Phillip R. Pittman, e Gerald W. Parker, Anthrax Vaccine: Evidence for Safety and Efficacy against Inhalational Anthrax, Journal of the American Medical Association 282, no. 22 (December 1999): 21046.95. G. G. Wright, T. W. Green, e R. G. Kanode Jr., Studies on Immunity in Anthrax, v: Immunizing Activity of Alum-Precipitated Protective Antigen, Journal of Immunology 73 (1954): 38791.ColaboradoresO Coronel (Dr.) Jim A. Davis (Bacharelado, DVM, Texas A&M University; Doutorado, University of Texas) tem, atualmente, dois cargos. E vice-diretor do USAF Counterproliferation Center [Centro de Contraproliferacao da FAe/ EUA] e, tambem, vice-diretor do Departamento de Futuros Conflitos, Air War College. Tambem foi representante do Ministerio da Saude [Surgeon Generals Chair] na Air University, comandante do 48th Esquadrao de Saude Aeroespacial, Base da Real Forca Aerea em Lakenheath, Reino Unido e chefe da Saude Publica Militar na Base Aerea Ellsworth, South Dakota, e na Base Aerea Loring, Maine. Tem sido frequentemente convidado como palestrante e conferencista para falar sobre bioterrorismo e guerra quimica e biologica. O Coronel Davis tem o curso do Air War College.A Dra. Anna Johnson-Winegar (Bacharelado, Hood College; Mestrado, Doutorado, Catholic University of America) e vice-assistente do Secretario de Defesa, para Defesa Quimica/Biologica. Ela e o unico membro do OSD em quem